Clinical trial NCT04408365: Endothelial Function, Inflammation and Organ Dysfunction in COVID-19
Official title: Endothelial Function, Inflammation, and Organ Dysfunction in Critically Ill Patients With COVID-19
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: COVID
Shock
Lead sponsor: Guy's and St Thomas' NHS Foundation Trust
Sponsor class: OTHER
Collaborators: name: King's College Hospital NHS Trust
First posted: 2020-05-29
Enrollment: 82
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult COVID-19 patients who are admitted in intensive care units

Brief summary: COVID-19 is a rapidly evolving pandemic with approximately 5% of all patients which require intensive care unit admission. In critically ill patients infected with COVID-19, approximately 15% had severe shock requiring medications to increase blood pressure. It appears that blood vessel tone is altered and microcirculation is not well regulated in patients with COVID-19. The underlying pathophysiology and contributing factors are unknown. The association with subsequent organ dysfunction and outcome is also unclear. Therefore, the investigators aim to investigate serial changes of relevant biomarkers in this population to improve the understanding of this disease, to investigate the association with clinically important outcomes and to find out how best to treat patients. The data will serve to develop strategies for individualised management of this high-risk group.

Detailed description: COVID-19 is a rapidly evolving pandemic with approximately 5% of all patients requiring admission to an intensive care unit. In critically ill patients infected with COVID-19, acute respiratory distress syndrome (ARDS) is found in 40%, 11.9% required continuous renal replacement therapy (RRT), and 13.4% had vasodilatory shock.

Currently, supportive treatment is the mainstay treatment, with fluid administration and vasopressors for haemodynamic support and lung-protective ventilation in patients with severe respiratory failure.3 Targeted drugs, antiviral therapies, and vaccines are still currently being developed, but there is currently insufficient evidence to recommend any drug over another.

Dysregulation of vasomotor tone and alteration of microcirculatory function are common in patients infected with COVID-19. The underlying pathophysiology and contributing factors are unknown. The association with subsequent organ dysfunction and outcome is also unclear.

Circulating bio-adrenomedullin regulates vascular tone and endothelial permeability during sepsis, and has been shown to associate with 28-day mortality, vasopressor requirement, RRT, and positive fluid balance. Proenkephalin is a biomarker of glomerular function, and was shown to elevate in patients with acute kidney injury (AKI), especially in those with persistent AKI, and major adverse kidney events. Dipeptidyl peptidase 3 (DPP-3) is a myocardial depressant factor, which is involved in angiotensin II cleavage. High DPP-3 levels were associated with severe organ dysfunction and short-term mortality. In critically ill patients, COVID-19 has been reported to be associated with cardiovascular dysfunction and high mortality.

The renin-angiotensin-aldosterone system (RAAS) may be linked to the pathogenesis of COVID-19. The coronavirus receptor utilizes angiotensin converting enzyme 2 (ACE2) to enter target cells. Endogenous angiotensin II is hypothesized to prevent binding of coronavirus to ACE2, causing internalization and downregulation of ACE2, and causing lysosome-mediated destruction of ACE2. There are no human studies in COVID-19 patients to confirm this hypothesis yet.

There is very little knowledge of underlying pathogenesis in patients with COVID-19 and vasodilatory shock. Therefore, the investigators aim to investigate serial changes of relevant biomarkers in this population to give further understanding of this disease and to investigate the association with clinically important outcomes. The data will serve to develop strategies for individualized management of this high-risk group.

Eligibility criteria: Inclusion Criteria:

1. Adult patients (≥ 18 years old) admitted to intensive care units
2. Confirmed or suspected severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection resulting in coronavirus disease 2019 (COVID-19)

Exclusion Criteria:

None

Primary outcomes:
measure: Change of plasma bio-adrenomedullin
timeFrame: Day 1-7 after intensive care unit admission
measure: Change of plasma proenkephalin
timeFrame: Day 1-7 after intensive care unit admission
measure: Change of plasma dipeptidyl peptidase-3
timeFrame: Day 1-7 after intensive care unit admission
measure: Change of plasma renin
timeFrame: Day 1-7 after intensive care unit admission
measure: Change of plasma angiotensin II
timeFrame: Day 1-7 after intensive care unit admission
Secondary outcomes:
measure: Duration of vasodilatory shock
timeFrame: 7 and 28 days
measure: Acute kidney injury
timeFrame: 7 and 28 days
measure: Need for renal replacement therapy
timeFrame: 7 and 28 days
measure: Duration of ventilation
timeFrame: 7 and 28 days
measure: Duration of extracorporeal membrane oxygenation
timeFrame: 7 and 28 days
measure: Mortality
timeFrame: 28 days
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Guy's & St Thomas' Hospital
Study officials:
affiliation: Guy's & St Thomas' Hospital
name: Nuttha Lumlertgul, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: